Beta

Jasper therapeutics, inc.JSPRW.US Overview

US StockHealthcare
(No presentation for JSPRW)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

JSPRW AI Insights

JSPRW Overall Performance

JSPRW AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

JSPRW Recent Performance

-

Jasper therapeutics, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

JSPRW PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check JSPRW's Trend

JSPRW Key Information

JSPRW Valuation Metrics

JSPRW Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

Price of JSPRW

JSPRW FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

JSPRW Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.66
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-0.69%
3-Year Revenue Growth
-%
3-Year Profit Growth
34.95%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.66
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-0.69%
3-Year Revenue Growth
-%
3-Year Profit Growth
34.95%

  • When is JSPRW's latest earnings report released?

    The most recent financial report for Jasper therapeutics, inc. (JSPRW) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating JSPRW's short-term business performance and financial health. For the latest updates on JSPRW's earnings releases, visit this page regularly.

  • How much cash does JSPRW have?

    At the end of the period, Jasper therapeutics, inc. (JSPRW) held Total Cash and Cash Equivalents of 28.69M, accounting for 0.8 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is JSPRW's EPS continuing to grow?

    According to the past four quarterly reports, Jasper therapeutics, inc. (JSPRW)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.32. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of JSPRW?

    Jasper therapeutics, inc. (JSPRW)'s Free Cash Flow (FCF) for the period is 614.12K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 102.89% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of JSPRW?

    The latest valuation data shows Jasper therapeutics, inc. (JSPRW) has a Price-To-Earnings (PE) ratio of -0.96 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.